<DOC>
	<DOC>NCT02944552</DOC>
	<brief_summary>The test adopted the superiority design of multi center, randomized, double-blind, positive control drug, dose finding, using two simulation skills. The qualified subjects, according to the ratio of 1:1:1, were randomized into low dose group and high dose group and positive drug control group, and received a treatment course of 8 weeks, all individuals were followed up for 4 weeks after drug withdrawal.</brief_summary>
	<brief_title>A Multicenter, Randomized, Double-blind Clinical Trial Was Conducted to Evaluate the Efficacy and Safety of Bicyclol in the Treatment of Acute Drug-induced Liver Injury and to Screen Biomarkers for Prognosis</brief_title>
	<detailed_description />
	<mesh_term>Drug-Induced Liver Injury</mesh_term>
	<mesh_term>Polyene phosphatidylcholine</mesh_term>
	<criteria>1. 18~70 years old, male or female 2. The clinical diagnosis of acute druginduced liver injury standard: evaluation of RUCAM causality scale score more than or equal to 6 points. If the evaluation of RUCAM causality scale score is 3~5,the DILI patient needs three liver disease experts to confirm, and the opinion of the three liver specialists are consensus 3. The serum ALT is between 3and 8 times ULN, but TBiL is less than or equal to 2 times ULN 4. Liver biochemical abnormalities lasted less than 90 days 5. Patients can understand after they know the nature of the experiment, the nature of the disease, the characteristics of drugs, related treatment methods and the risk they may need to bear if they participate in the test, and sign the informed consent. 1. Other reasons cause liver damage, such as viral hepatitis, alcoholic liver disease, and nonalcoholic fatty liver disease and autoimmune liver disease. 2. Acute liver failure or liver function decompensation patient perform, such as hepatic encephalopathy, ascites, albumin is less than or equal to 35g / L, prothrombin time compared with normal control extended for more than 3 seconds. 3. Serum creatinine is greater than the upper limit of the normal value 1.5 times above. 4. Serious heart, lung, brain, kidney, gastrointestinal and systemic diseases. 5. At the same time taking the drugs that affect observation of curative effect of this experiment. 6. The drug allergy or intolerance 7. With no ability to express their complaints, such as mental illness and severe neurosis patient. 8. The patient can not cooperate and poor compliance. 9. Pregnant and lactating women or women preparing for pregnancy 10. The patient participated in other clinical trials in 3 months before entering the group, within 1 week after application of other hepatoprotective. 11. The researchers believe not suitable.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>